Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ігор Валерійович ХалецькийfiledCriticalІгор Валерійович Халецький
Priority to UAU201402513UpriorityCriticalpatent/UA92073U/en
Publication of UA92073UpublicationCriticalpatent/UA92073U/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
A method for the combined treatment of the locally advanced gastric cancer comprises chemo- and radiotherapy followed by the surgery. Following the catheterization of the femoral lymphatic vessel, the endolymphatic chemotherapy is provided (for example with 5-fluorouracil 350-550 mg/m) supplemented with preoperative low-fractionated teletherapy with fraction dose of 2.5 Gy and total boost dose of 40 Gy delivered to the tumor and the areas of the regional metastasizing. After neoadjuvant chemo- and radiotherapy, the surgery follows in the required extent, namely gastrectomy or subtotal gastric resection with lymph dissection D2. Postoperatively, the endolymphatic or systemic chemotherapy follows according to the standardized schedules.
UAU201402513U2014-03-132014-03-13Method for combined treatment of locally advanced gastric cancer
UA92073U
(en)
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр радиологии» Министерства здравоохранения Российской Федерации (ФГБУ «НМИЦ радиологии» Минздрава России)
Method for integrated treatment of stomach cancer in growth in the body of the pancreas
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр радиологии» Министерства здравоохранения Российской Федерации (ФГБУ «НМИЦ радиологии» Минздрава России)
Method for integrated treatment of stomach cancer in growth in the body of the pancreas
isolated chimeric antibody, isolated polypeptide, expression vector, cell, methods for producing the chimeric antibody, for reducing growth and / or invasiveness of a neoplastic cell, for treating an individual who has a neoplasm, and for treating or preventing tumor progression or metastasis, pharmaceutical composition, and kit
Multi-arm, nonrandomized, open-label phase Ib study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling